Acrivon Therapeutics Reports Q1 2025 Progress and Financials

Acrivon Therapeutics, Inc. ( (ACRV) ) has released its Q1 earnings. Here is a breakdown of the information Acrivon Therapeutics, Inc. presented to its investors.

Acrivon Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision oncology medicines using its proprietary Generative Phosphoproteomics AP3 platform. The company recently reported its first-quarter 2025 financial results and business highlights, showcasing significant progress in its clinical pipeline and executive team expansion.

In the first quarter of 2025, Acrivon Therapeutics highlighted positive interim data from its ACR-368 Phase 2b study in endometrial cancer patients, demonstrating promising response rates and duration of response. Additionally, the company completed three dose escalation cohorts in the ACR-2316 Phase 1 trial, observing tumor shrinkage at lower doses than projected for Phase 2, and presented mechanisms underlying its superior preclinical activity.

Key financial metrics for the quarter included a net loss of $19.7 million, an increase from $16.5 million in the same period of 2024, primarily due to increased research and development expenses. The company reported cash, cash equivalents, and marketable securities of $164.8 million, expected to fund operations into the second quarter of 2027.

Acrivon also announced strategic appointments, including Mansoor Raza Mirza, M.D., as chief medical officer, bringing extensive experience in oncology trials and regulatory approvals. The company plans to provide updates on its ongoing trials and advance new drug discovery programs throughout 2025.

Looking ahead, Acrivon Therapeutics remains focused on advancing its clinical programs and leveraging its AP3 platform to develop innovative oncology treatments, with a strong cash position to support its strategic initiatives.